- Global Pharma News & Resources

CBD Global Sciences Launches Legacy Distribution Group, a Distribution Company That Focuses on CBD Infused Products

DGAP-News: CBD Global Sciences, Inc. / Key word(s): Miscellaneous
18.02.2021 / 13:30
The issuer is solely responsible for the content of this announcement.

CBD Global Sciences Launches Legacy Distribution Group, a Distribution Company That Focuses on CBD Infused Products

Denver, Colorado, via NewMediaWire -- CBD Global Sciences, Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt:GS3), ("CBD Global" or the "Company"), is pleased to share that it has created a new distribution company called Legacy Distribution Group.

Legacy Distribution Group, "Legacy Distribution" (Denver, CO) is one of the country's first CBD-only Direct Store Delivery (DSD) distributors. Until now, CBD brands have had to rely heavily on distributors that may be as new to CBD as the customers they service. While many of these distributors have a long track record of success, their lack of CBD expertise and broader, mostly traditional brand portfolios routinely result in the underperformance of the CBD brands they represent. This is the problem Legacy aims to solve. By providing best-in-class service and unmatched CBD expertise, Legacy's curated approach is designed specifically to help maximize the growth and market penetration of new and existing CBD brands. Currently, Legacy has begun vetting a new round of CBD brands to be included in their growing portfolio.

CBD Global has enlisted a team of highly skilled distribution and sales managers that have honed their expertise in large scale DSD over the past several decades. The assembly of this team is a collaborative effort with people and companies that have successfully managed and navigated the creation and growth of distribution channel services and we are pleased to launch this project. The team at Legacy Distribution collectively has nearly three decades of experience in DSD operations and nearly a decade long track record of sales success in the CBD space. This unique combination results in an unparalleled ability to successfully open and effectively service new accounts on behalf of the brands in their portfolio. Legacy Distribution has acquired distribution and sales routes that consist of approximately 1,000 points of distribution in the Colorado and surrounding region. These routes were established with CBD infused product in early 2019 and continue to grow with seven major brands being represented.

Brad Wyatt, CEO of CBD Global Sciences, shared, "Direct store delivery is a big piece of my corporate background, running large scale distribution facilities for companies like Target Corporation, Sears Roebuck and Federal Mogul. I've found that to be successful in this space leadership needs to surround themselves with solid operators that possess incredible relationships. In the coming months we will be able to share more information about the team, the growing list of distribution agreements with multiple large-scale brands and the likes. We are extremely excited to bring this to the CBD industry with the intent to provide a quicker, more efficient and more affordable path to sales for the CBD Brands that are trying to get their products on the shelf."


CBD Global Sciences, Inc., is a vertically integrated hemp-based CBD producer and branding investment vehicle which currently owns two product categories, branded under the name Aethics(TM) ( and CANNAOIL (, which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals, Hydration products and Confectionary products. CBD Global Sciences hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

CBD Global Sciences, through its wholly owned subsidiary, Strasburg Pharms, grows and operates irrigated land in Colorado, that grows hemp with only all-natural Colorado water, soil, sun and nutrients and NEVER sprayed with pesticides or chemicals. Our genetics are hand selected and maintained to present the best cannabinoid profile with extremely high CBD.

For further information, please contact Bruce Nurse, Investor Relations, (888) 401-2239,


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to future developments and the business and operations of the Corporation after the CSE listing. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. Readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

18.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: CBD Global Sciences, Inc.
225 Union Blvd., Suite 350
CO 80228 Denver
United States
ISIN: CA12482U1057
Listed: Regulated Unofficial Market in Frankfurt, Munich, Stuttgart; Toronto
EQS News ID: 1169136

End of News DGAP News Service

Editor Details

Last Updated: 18-Feb-2021